) recently announced that data on its pipeline candidate RLX030
was published in the
European Heart Journal
and also presented at the European Society of Cardiology (ESC)
Data from the phase III study (RELAX-AHF) revealed that
treatment with RLX030 improved symptoms and mortality rates
across multiple subgroups of patients suffering from acute heart
Further, the addition of RLX030 to conventional treatment led
to improvements in breathlessness and mortality at 6 months
across all pre-specified subgroups.
Novartis is developing RLX030 for the treatment of AHF.
We note that RLX030 is currently under review in several
countries including the U.S. and the EU.
In Jun 2013, the U.S. Food and Drug Administration (FDA)
granted "Breakthrough Therapy" designation to RLX030. The
designation should help fasten the development and review process
of the candidate.
As per Novartis, as many as 3.5 million AHF incidents take
place in the U.S. and EU annually. The incidents are expected to
go up further as the population ages.
We note that Novartis had another candidate LCZ696, which is
in phase III development, for the treatment of chronic heart
We are encouraged by the pipeline progress at Novartis. In Aug
2013, Novartis obtained 'Breakthrough Therapy' designation from
the FDA on another pipeline candidate, BYM338, for the sporadic
inclusion body myositis indication.
Novartis currently carries a Zacks Rank #3 (Hold). Right now,
Forest Laboratories Inc
) look attractive with a Zacks Rank #2 (Buy).
FOREST LABS A (FRX): Free Stock Analysis
IRONWOOD PHARMA (IRWD): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
To read this article on Zacks.com click here.